| Autologous Program | Target(s) | Indication(s) | Discovery | IND-enabling | Phase 1 | Phase 2 | Phase 3 | Commercial rights |
|---|---|---|---|---|---|---|---|---|
| CRG-023 (tri-specific, tri-cistronic CAR T) | CD19 CD20 CD22 |
B-cell malignancies |  | |||||
| CRG-023 (tri-specific, tri-cistronic CAR T) | |||||
|---|---|---|---|---|---|
| Discovery | IND-enabling | Phase 1 | Phase 2 | Phase 3 | Commercial rights |
| Target: CD19 CD20 CD22 | |||||
| Indication: B-cell malignancies | |||||
| Allogeneic Platform | Applications | Indication(s) | Discovery | IND-enabling | Phase 1 | Phase 2 | Phase 3 | Commercial rights |
|---|---|---|---|---|---|---|---|---|
| Universal Vector | CAR T-cell therapy | Potential for hem onc, solid tumors, other | | |||||
| Universal Vector | |||||
|---|---|---|---|---|---|
| Discovery | IND-enabling | Phase 1 | Phase 2 | Phase 3 | Commercial rights |
| Target: CAR T-cell therapy | |||||
| Indication: Potential for hem onc, solid tumors, other | |||||